• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Different dynamics of soluble inflammatory mediators after clearance of respiratory SARS-CoV-2 versus blood-borne hepatitis C virus infec

tetano

Editor, Senior Moderator
Sci Rep


. 2024 Nov 22;14(1):29013.
doi: 10.1038/s41598-024-79909-8. Different dynamics of soluble inflammatory mediators after clearance of respiratory SARS-CoV-2 versus blood-borne hepatitis C virus infections

Antonia Zeuzem[SUP] 1 2 3 4 5 [/SUP], Saumya Dileep Kumar[SUP] 2 4 [/SUP], Carlos Oltmanns[SUP] 1 2 3 4 5 [/SUP], Moana Witte[SUP] 1 2 3 4 5 [/SUP], Jasmin Mischke[SUP] 1 2 3 4 5 [/SUP], Nora Drick[SUP] 6 7 [/SUP], Jan Fuge[SUP] 6 7 [/SUP], Isabell Pink[SUP] 6 7 [/SUP], Jan Tauwaldt[SUP] 1 2 3 4 5 [/SUP], Jennifer Debarry[SUP] 2 4 [/SUP], Thomas Illig[SUP] 8 [/SUP], Heiner Wedemeyer[SUP] 1 3 5 [/SUP], Benjamin Maasoumy[SUP] 1 [/SUP], Yang Li[SUP] 2 4 5 9 [/SUP], Anke R M Kraft[SUP] 1 2 3 4 5 [/SUP], Markus Cornberg[SUP] 10 11 12 13 14 [/SUP]



Affiliations
Abstract

Viral infections can be acute or chronic, with the immune system pivotal in immunopathogenesis. The potential reversibility of inflammation post-viral elimination is of current interest. This study compares the dynamics of soluble inflammatory mediators (SIM) during and after respiratory infections with SARS-CoV-2 and blood-borne acute and chronic hepatitis C virus (HCV) infections. The study included patients with acute HCV (n = 29), chronic HCV (n = 54), and SARS-CoV-2 (n = 39 longitudinal, n = 103 cross-sectional), along with 30 healthy controls. Blood samples were collected at baseline, end of treatment/infection, and during follow-up (up to 9 months). SIMs were quantified using the HD-SP-X Imaging and Analysis System™. At baseline, SIM profiles in acute SARS-CoV-2 and HCV infections were significantly elevated compared with controls. During follow-up, SIM decline was less pronounced in acute and chronic HCV infections after successful therapy than in SARS-CoV-2 infections. Most SIM in the SARS-CoV-2 cohort normalized within 3 months. In chronic HCV, SIM were higher in cirrhotic than noncirrhotic patients post-HCV elimination. Dynamics of SIM after viral elimination vary between blood-borne acute and chronic HCV infections and respiratory SARS-CoV-2 infections. Immunological imprints 3-9 months after HCV elimination appear more pronounced than after SARS-CoV-2 infection.

Keywords: COVID-19; Chemokines; Cirrhosis; Cytokines; Direct-acting antiviral; Hepatitis C virus; Immune mediators; Inflammation; Long-COVID; Proteomics; SARS-CoV-2 infection; Sustained virological response.

 
Back
Top Bottom